Related by context. Frequent words. (Click for all words.) 76 submitted Biologics License 74 supplemental Biologics License Application 70 Biologics License Application BLA 69 Marketing Authorization Application MAA 68 sBLA 68 FDA Accepts 68 ZALBIN 68 Act PDUFA date 68 application sNDA 67 Pivotal Phase III 66 Biologics License Application 66 Surgical Adhesive 66 submitted Marketing Authorization 65 sNDA 65 Zalbin 65 Marketing Authorization Application 64 Drug Application 64 Clevudine 64 Investigational Device Exemption 64 NASDAQ CRXL 63 VALSTAR 63 Phase III Clinical Trial 63 Crucell NV Euronext 63 Advancing Drugs 62 NEBIDO 62 sodium phosphate monobasic monohydrate 62 Omigard 62 Fast Track designation 62 Orphan Drug status 62 FDA approvable letter 62 SILENOR TM 62 Nexavar ® 62 Aradigm Corporation 62 New Drug Application 62 Orphan Drug designation 62 pseudobulbar affect PBA 62 taliglucerase alfa 61 FDA Orphan Drug 61 Icatibant 61 Generic Version 61 dalbavancin 61 Zelrix 61 injection USP 61 Panzem R 61 Pirfenidone 61 Completes Enrollment 61 Company Nasdaq PRGO 61 Fast Track Designation 61 Patient Enrollment 61 Phenoptin 61 R sorafenib tablets 61 Clinical Trial Application 61 alogliptin 60 prGCD 60 sodium Injection 60 Rebif ® 60 phase IIb clinical 60 CHEAP ONLINE PHARMACY LOW 60 BENLYSTA 60 Oscient Pharmaceuticals Corporation 60 NASDAQ IMCL 60 OTCQX RHHBY 60 Nasdaq VRTX 60 Initiates Phase 60 bazedoxifene 60 ALIM 60 Phase IIb trials 60 Priority Review 60 orphan medicinal product 60 Orphan Drug Designation 60 Presents Positive 60 REVLIMID R 60 Market Approval PMA 60 Rhucin ® 60 Medicinal Products EMEA 60 refractory Hodgkin lymphoma 60 Positive Opinion 60 IND submission 59 Pivotal Trial 59 Pivotal Phase 59 Drug Administration USFDA 59 confirmatory Phase 3 59 sodium phosphate dibasic anhydrous 59 Solzira 59 alvimopan 59 CHEAP ONLINE PHARMACY BEST 59 Strativa 59 NASDAQ ARIA 59 REVLIMID lenalidomide 59 cutaneous T cell 59 Investigational Device Exemption IDE 59 lymphoma CTCL 59 Dynavax Technologies Corporation 59 New Drug IND 59 USFDA approval 59 human antithrombin 59 Orphan Drug Status 59 IIa trial 59 Onalta 58 Phase III Trial 58 Nasdaq REGN